Senestech (SNES) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
24 Dec, 2025Executive summary
Achieved record Q4 and FY2024 results with quarterly revenue up 70% year-over-year and gross margin at 61%, driven by the Evolve product line and e-commerce growth.
Operational efficiencies and cost reductions led to the smallest quarterly adjusted EBITDA loss in company history, with annual expenses reduced by $2 million.
Net loss narrowed to $1.3 million in Q4 2024 from $1.7 million in Q4 2023; adjusted EBITDA loss improved to $1.1 million from $1.6 million.
Strategic financing completed, raising over $2 million in Q1 2025 through ATM facility and warrant exercises, providing capital to accelerate progress toward cash flow break-even.
Evolve product line expanded into new markets, including e-commerce, municipal, warehousing, and international sectors.
Financial highlights
Q4 2024 revenue reached $501,000, a 70% increase year-over-year; FY2024 revenue was $1.9 million, up 56%.
Gross margin for Q4 was 61%, up from 44% in Q4 2023; gross profit dollars increased 136% year-over-year.
E-commerce sales grew 206% in Q4 year-over-year, representing 55% of Q4 revenue.
Evolve Rat accounted for 52% of Q4 sales, Evolve Mouse 24%, and ContraPest declined 51% as customers converted to Evolve.
Operating expenses for Q4 2024 were $1.1 million, down from $1.8 million in Q4 2023.
Outlook and guidance
Cash flow break-even revenue threshold reduced to $7 million annually, down from $12 million, due to cost savings and higher margins.
Targeting cash flow break-even in the near term, with potential to achieve quickly through large retail, municipal, or international sales.
Management anticipates continued progress toward profitability through cost reductions and margin improvements.
No specific revenue forecast for 2025, but management expects continued growth from initiatives started in 2024.
Latest events from Senestech
- E-commerce drove 20% revenue growth, margin gains, and cash runway extends to Q2 2027.SNES
Q4 202512 Mar 2026 - Record revenue and margin gains, but cash constraints require new financing for profitability.SNES
Q2 20241 Feb 2026 - Record growth fueled by innovative fertility control products and expanding global distribution.SNES
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Record Q3 revenue and margin gains fueled by Evolve products and e-commerce growth.SNES
Q3 202414 Jan 2026 - Evolve products now drive 70% of sales, fueling rapid growth and improved profitability.SNES
Lytham Partners 2025 Industrials & Basic Materials Investor Summit26 Dec 2025 - Resale of 1.5M+ shares from warrant exercises funds humane rodent control, but financial risk remains.SNES
Registration Filing16 Dec 2025 - Resale of 1,036,279 shares tied to warrant exercises supports operations amid ongoing losses.SNES
Registration Filing16 Dec 2025 - Innovative pest control firm seeks up to $15M via flexible at-the-market equity offering.SNES
Registration Filing16 Dec 2025 - Offering up to $15M in securities amid ongoing losses and regulatory-driven growth plans.SNES
Registration Filing16 Dec 2025